Earnings summaries and quarterly performance for Profound Medical.
Research analysts who have asked questions during Profound Medical earnings calls.
BH
Benjamin Haynor
Lake Street Capital Markets
3 questions for PROF
Also covers: BFLY, EKSO, IDXG +6 more
John McAulay
Stifel
3 questions for PROF
Also covers: AORT, ATRC
Michael Freeman
Raymond James
3 questions for PROF
Also covers: ACOG, BHC, HWAIF +2 more
Scott McAuley
Paradigm Capital
3 questions for PROF
RS
Rahul Sarugaser
Raymond James
2 questions for PROF
Also covers: ONCY
Brian Gagnon
Gagnon Securities
1 question for PROF
FW
Frederick Wise
Stifel
1 question for PROF
Also covers: AORT, ATRC, AVNS +13 more
MS
Michael Sarcone
Jefferies
1 question for PROF
Also covers: ALC, ALGN, AXGN +12 more
Recent press releases and 8-K filings for PROF.
Profound Medical Corp. Announces Mount Sinai Adopts TULSA-PRO® System
PROF
New Projects/Investments
- Profound Medical Corp. announced that Mount Sinai Hospital successfully treated its first prostate cancer patient using the TULSA-PRO® system on January 15, 2026.
- Mount Sinai is the first health system in the New York Metro Area to offer the AI-driven, MRI-guided, incision-free TULSA Procedure for prostate disease patients.
- The TULSA-PRO® system is a commercial-stage medical device that provides an incision-free therapy for prostate cancer and benign prostatic hyperplasia (BPH), designed to preserve continence and sexual function, and is CE marked, Health Canada approved, and 510(k) cleared by the U.S. FDA.
Jan 15, 2026, 12:35 PM
Profound Medical Corp. Surpasses 2025 TULSA-PRO® Installed Base Goal
PROF
Guidance Update
Revenue Acceleration/Inflection
- Profound Medical Corp. exceeded its 2025 TULSA-PRO® installed base goal, reaching 78 systems as of December 31, 2025, surpassing its previously announced target of 75 installs.
- The company's qualified sales pipeline for TULSA-PRO® grew to 97 new systems classified within the "Verify, Negotiate and Contracting" stages at year-end.
- Profound's CEO and Chairman, Arun Menawat, stated that the growing installed base is expected to lead to higher patient treatment rates and continued growth of high-margin recurring revenue.
Jan 12, 2026, 4:37 PM
Profound Medical Exceeds TULSA-PRO® Installed Base Goal for 2025
PROF
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Profound Medical Corp. announced that its TULSA-PRO® system installed base reached 78 as of December 31, 2025, surpassing its previously announced goal of 75 installs.
- The company's TULSA-PRO qualified sales pipeline grew to 97 new systems in the "Verify, Negotiate and Contracting" stages by year-end.
- Profound's CEO expects the growing installed base to drive higher patient treatment rates and continued growth of high-margin recurring revenue.
- The company plans to release its fourth quarter and full year 2025 financial results near the end of February 2026.
Jan 12, 2026, 1:00 PM
Profound Medical's TULSA-PRO System Used in First Commercial Case at Johns Hopkins
PROF
Product Launch
New Projects/Investments
- Johns Hopkins Medicine has treated its first non-clinical-trial prostate cancer patient using Profound Medical Corp.'s TULSA-PRO® system.
- This event marks the official launch of TULSA-PRO at Johns Hopkins Medicine, coinciding with the opening of their new interventional MRI (iMRI) suite.
- The TULSA-PRO® system is an AI-powered, MRI-guided, incision-free therapy for prostate cancer and benign prostatic hyperplasia (BPH), which has received U.S. FDA clearance.
Jan 6, 2026, 6:39 PM
Profound Medical: Johns Hopkins Hospital Treats First Commercial TULSA-PRO Case
PROF
Product Launch
- Profound Medical Corp. announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the Company’s TULSA-PRO® system.
- This event marks the official launch of TULSA-PRO at Johns Hopkins, coinciding with the opening of their new interventional MRI suite.
- The TULSA-PRO system is an AI-powered, MRI-guided, incision-free therapy designed to treat prostate cancer and benign prostatic hyperplasia (BPH).
- Key benefits of the TULSA Procedure include no procedural blood loss, no overnight hospital stay, and a quicker return to everyday life, while minimizing typical side effects.
Jan 6, 2026, 12:45 PM
Profound Medical Corp. Announces Completion of Private Placement
PROF
New Projects/Investments
- Profound Medical Corp. completed a private placement on December 30, 2025, issuing 921,428 common shares to Canadian investors.
- The offering generated approximately US$6.45 million in gross proceeds at a price of US$7.00 per common share.
- Net proceeds are intended for sales and marketing expansion, working capital, research and development, strategic transactions, and general corporate purposes.
- The common shares are subject to a four-month-plus-one-day hold period under Canadian securities laws, and the company plans to file a U.S. SEC registration statement for resale within four months.
Dec 30, 2025, 9:30 PM
Profound Medical Corp. Closes $36 Million Registered Direct Offering
PROF
- Profound Medical Corp. has closed a registered direct offering, generating approximately $36 million in gross proceeds.
- The offering involved the sale of 5,142,870 common shares at a purchase price of $7.00 per share.
- The company intends to use the net proceeds for expansion of its sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes.
- Additionally, Profound plans to complete a private placement to certain Canadian purchasers, expected to close on or prior to December 30, 2025.
Dec 23, 2025, 1:00 PM
Profound Medical Corp. Announces Up to $40 Million Financing
PROF
New Projects/Investments
- Profound Medical Corp. announced a financing of up to $40 million, comprising a $36 million registered direct offering and a subsequent $4 million private placement.
- The registered direct offering involves the sale of 5,142,857 common shares at a purchase price of $7.00 per share, with an expected closing date around December 22, 2025.
- The private placement will offer up to 571,428 common shares at $7.00 per share, anticipated to close on or prior to December 30, 2025.
- The net proceeds from the offering will be used for expansion of sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes.
- Konik Capital Partners, LLC is acting as the exclusive placement agent, receiving a 5.0% cash fee of the gross proceeds and expense reimbursement up to $100,000.
Dec 19, 2025, 9:36 PM
Profound Medical Corp. Announces Up to $40 Million Financing
PROF
New Projects/Investments
- Profound Medical Corp. announced a financing plan on December 19, 2025, totaling up to $40 million.
- This includes a registered direct offering of 5,142,857 common shares at $7.00 per share, expected to generate approximately $36 million in gross proceeds and close around December 22, 2025.
- A subsequent private placement in Canada of up to 571,428 common shares at $7.00 per share is planned, aiming for up to $4 million in gross proceeds and expected to close by December 30, 2025.
- The net proceeds from the offering are intended for expansion of sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes.
Dec 19, 2025, 1:45 PM
Profound Medical to Launch AI-Powered BPH Module and Present New Clinical Data
PROF
Product Launch
New Projects/Investments
- Profound Medical Corp. announced the upcoming launch of its TULSA-AI® Volume Reduction module for optimizing the treatment of benign prostatic hyperplasia (BPH) at the Radiological Society of North America (RSNA) meeting, taking place from November 30 to December 4, 2025.
- The new AI-powered module is expected to streamline workflow and reduce procedure times, which is anticipated to triple Profound's total available market in prostate disease to approximately 600,000 patients annually.
- The company will also present new clinical data on TULSA-PRO for prostate cancer at both the RSNA and the Society for Urologic Oncology (SUO) meetings.
Nov 28, 2025, 6:55 PM
Quarterly earnings call transcripts for Profound Medical.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more